Relypsa (RLYP) Veltassa 'Off To A Strong Start' - Spherix Global Insights
Get Alerts RLYP Hot Sheet
Join SI Premium – FREE
Spherix Global Insights said a recent study with 101 US nephrologists in late January 2016 showed "promising activity" for Relypsa's (NASDAQ: RLYP) Veltassa.
Prior to launch, but following the October approval, unaided awareness of Veltassa was high which likely paved the way for early trial. In addition to the 20% of surveyed nephrologists who already have prescribed Veltassa to at least one patient, 17% report that they intend to start prescribing "right away." Nephrologists report a high unmet need with a large pool of patients who would be considered candidates for Veltassa.
One of the greatest barriers to Veltassa use noted in the study is the boxed warning calling for a six-hour dose separation with other medications due to potential drug-drug interactions. 24% of those surveyed indicated that this would have a significant impact on their use. However, since the fielding, Relypsa provided updated information on the drug-drug interactions, suggesting that a shorter dose separation window may be possible. A follow up survey in February will highlight the impact this update has had on diminishing this barrier.
A rapid uptake is critical for Veltassa which faces competition from AstraZeneca's ZS-9 (zirconium silicate), another novel potassium binder with a PDUFA date in May. Awareness of ZS-9 is also high and although most nephrologists feel that it is too early to point to one agent as more advantageous, a small subset views ZS-9 as the superior product.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citius Pharmaceuticals (CTXR) Announces FDA Acceptance of BLA Resubmission of LYMPHIR for Treatment of Adults with R/R Cutaneous T-Cell Lymphoma
- WW International, Inc. (WW) is on track to beat its previously provided first quarter fiscal 2024 guidance
- Roblox (RBLX) Trades at Low, Down 8%
Create E-mail Alert Related Categories
FDA, Short Sales, Trader TalkRelated Entities
PDUFASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!